Eli Lilly and Co
LSE:0Q1G
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
E
|
Eli Lilly and Co
LSE:0Q1G
|
US |
|
M
|
MTN Group Ltd
JSE:MTN
|
ZA |
|
Aspen Pharmacare Holdings Ltd
OTC:APNHF
|
ZA |
|
M
|
MSCI Inc
XBER:3HM
|
US |
|
Consti Oyj
LSE:0RD9
|
FI |
|
C
|
Chipotle Mexican Grill Inc
BMV:CMG
|
US |
|
Kuaishou Technology
LSE:0A74
|
CN |
|
Deutsche Bank AG
XETRA:DBK
|
DE |
|
B
|
BP PLC
XBER:BPE5
|
UK |
|
C
|
China Citic Bank Corp Ltd
SWB:D7C
|
CN |
|
Sun Life Financial Inc
TSX:SLF
|
CA |
|
A
|
Adidas AG
LSE:0OLD
|
DE |
Wall St Price Targets
0Q1G Price Targets Summary
Eli Lilly and Co
According to Wall Street analysts, the average 1-year price target for 0Q1G is 983.5048 CHF with a low forecast of 692.7763 CHF and a high forecast of 1 270.9641 CHF.
Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What you see on other sites is mostly sourced from sell-side analysts.
What is 0Q1G's stock price target?
Price Target
983.5048
CHF
According to Wall Street analysts, the average 1-year price target for 0Q1G is 983.5048 CHF with a low forecast of 692.7763 CHF and a high forecast of 1 270.9641 CHF.
What is the Revenue forecast for Eli Lilly and Co?
Projected CAGR
11%
Over the last 13 years, the compound annual growth rate for Revenue has been 8%. The projected CAGR for the next 8 years is 11%.
What is the Operating Income forecast for Eli Lilly and Co?
Projected CAGR
14%
Over the last 13 years, the compound annual growth rate for Operating Income has been 15%. The projected CAGR for the next 8 years is 14%.
What is the Net Income forecast for Eli Lilly and Co?
Projected CAGR
17%
Over the last 13 years, the compound annual growth rate for Net Income has been 13%. The projected CAGR for the next 8 years is 17%.
